Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX
NCT ID: NCT05372562
Last Updated: 2022-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2017-07-01
2022-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
NCT06268561
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
NCT06262737
Vision Improvement for Patients With Age-Related Macular Degeneration
NCT06198452
Retinal Oximtery Following Treatment for Diabetic Maculopathy
NCT01549132
A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
NCT01666821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with recurrent macular edema
after intravitreal injection of OZURDEX, patients with macular edema relapse during follow-up were recruited.
No interventions assigned to this group
patients without recurrent edema
after intravitreal injection of OZURDEX, patients without macular edema relapse during follow-up were recruited.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients with macular disease before surgery, such as age-related macular degeneration (ARMD), macular choroidal neovascularization (CNV), myopic macular degeneration, macular hole (MH), epiretinal membrane(ERM);
* patients with uveitis before surgery, including anterior, intermediate, posterior and generalized uveitis;
* patients with autoimmune disease, such as ankylosing spondylitis (AS), Vogt-Koyanagi-Harada (VKH) disease, Behcet disease.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chun Zhang
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Third Hosipital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00006761-M2022205
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.